Rubius Therapeutics to Announce First Quarter 2021 Financial Results
April 26 2021 - 8:00AM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines called
Red Cell Therapeutics™ for the treatment of cancer and autoimmune
diseases, today announced plans to report first quarter financial
results on Monday, May 10, 2021, before market open.
The company will not be hosting a teleconference in conjunction
with its financial results press release.
About Rubius TherapeuticsRubius
Therapeutics is a clinical-stage biopharmaceutical company
developing a new class of medicines called Red Cell Therapeutics™.
The Company’s proprietary RED PLATFORM® was designed to genetically
engineer and culture Red Cell Therapeutics™ that are selective,
potent and off-the-shelf allogeneic cellular therapies for the
potential treatment of several diseases across multiple therapeutic
areas. Rubius’ initial focus is to advance RCT™ product candidates,
for the treatment of cancer and autoimmune diseases, by leveraging
two distinct therapeutic modalities — potent cell-cell interaction
and tolerance induction. Rubius Therapeutics was recently named
among the Top Places to Work in Massachusetts by the Boston Globe,
and its manufacturing site was recently named 2020 Top 5 Best
Places to Work in Rhode Island among medium-sized companies by
Providence Business News. For more information, visit
www.rubiustx.com, follow us on Twitter or LinkedIn or like us on
Facebook.
Contacts:Elhan Webb, CFAVice President,
Investor
Relationselhan.webb@rubiustx.comMedia: Marissa
HanifyDirector, Corporate
Communicationsmarissa.hanify@rubiustx.com
Dan Budwick1AB +1 (973)
271-6085dan@1abmedia.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jul 2023 to Jul 2024